Skip to main
CRVO
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc has showcased a strong financial foundation with a cash position of $38.9 million, providing a sufficient operational runway into mid-2026, which is crucial for supporting ongoing clinical trials. The recent Phase 2b extension results for Neflamapimod demonstrated statistically significant improvements in clinical measures, indicating the potential efficacy of the product candidate in treating dementia with Lewy bodies. Furthermore, the company's increasing investment in research and development, reflected by a rise in R&D expenses to $18.8 million, underscores its commitment to advancing its clinical programs and optimizing product formulations.

Bears say

CervoMed Inc faces significant financial risks as it remains a clinical-stage biotechnology company with no revenue-generating products, having incurred continuous losses since its inception. The disappointing results from the RewinD-LB trial, attributed to lower than expected plasma drug concentrations leading to underdosing, raise concerns regarding the efficacy of its product candidate, Neflamapimod. Additionally, the competitive landscape, characterized by both existing and emerging therapies targeting similar neurological indications, poses a threat to the company's potential market penetration and pricing strategies.

CervoMed Inc (CRVO) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 8 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.